• 1
    DeLellis, R., Lloyd, R., Heitz, P. et al. (2004) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. IARC Press, Lyon, France, 147166.
  • 2
    Spencer, E., Pycock, C. & Lytle, J. (1993) phaeochromcytoma presenting as acute circulatory collapse and abdominal pain. Intensive Care Medicine, 19, 356357.
  • 3
    Goldstein, R.E., O'Neill, J.A. Jr, Holcomb, G.W. 3rd et al. (1999) Clinical experience over 48 years with pheochromocytoma. Annals of Surgery, 229, 755764; discussion 64-6.
  • 4
    Latif, F., Tory, K., Gnarra, J. et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science, 260, 13171320.
  • 5
    Mannelli, M., Castellano, M., Schiavi, F. et al. (2009) Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. Journal of Clinical Endocrinology and Metabolism, 94, 15411547.
  • 6
    Maher, E.R. & Eng, C. (2002) The pressure rises: update on the genetics of phaeochromcytoma. Human Molecular Genetics, 11, 23472354.
  • 7
    Mulligan, L.M., Kwok, J.B., Healey, C.S. et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature, 363, 458460.
  • 8
    Viskochil, D., Buchberg, A.M., Xu, G. et al. (1990) Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell, 62, 187192.
  • 9
    Cascon, A., Pita, G., Burnichon, N. et al. (2009) Genetics of pheochromocytoma and paraganglioma in Spanish patients. Journal of Clinical Endocrinology and Metabolism, 94, 17011705.
  • 10
    Amar, L., Bertherat, J., Baudin, E. et al. (2005) Genetic testing in pheochromocytoma or functional paraganglioma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23, 88128818.
  • 11
    Fokkema, I.F., Taschner, P.E., Schaafsma, G.C. et al. (2011) LOVD v. 2.0: the next generation in gene variant databases. Human Mutation, 32, 557563.
  • 12
    Baysal, B.E., Ferrell, R.E., Willett-Brozick, J.E. et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287, 848851.
  • 13
    Peczkowska, M., Cascon, A., Prejbisz, A. et al. (2008) Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nature Clinical Practice Endocrinology and Metabolism, 4, 111115.
  • 14
    Astuti, D., Latif, F., Dallol, A. et al. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. American Journal of Human Genetics, 69, 4954.
  • 15
    Burnichon, N., Briere, J.J., Libe, R. et al. (2010) SDHA is a tumor suppressor gene causing paraganglioma. Human Molecular Genetics, 19, 30113020.
  • 16
    Hao, H.X., Khalimonchuk, O., Schraders, M. et al. (2009) SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science, 325, 11391142.
  • 17
    Qin, Y., Yao, L., King, E.E. et al. (2010) Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genetics, 42, 229233.
  • 18
    Schlisio, S., Kenchappa, R.S., Vredeveld, L.C. et al. (2008) The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes and Development, 22, 884893.
  • 19
    Ladroue, C., Carcenac, R., Leporrier, M. et al. (2008) PHD2 mutation and congenital erythrocytosis with paraganglioma. New England Journal of Medicine, 359, 26852692.
  • 20
    Comino-Mendez, I., Gracia-Aznarez, F.J., Schiavi, F. et al. (2011) Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics, 43, 663667.
  • 21
    Bravo, E.L. & Gifford, R.W. Jr (1984) Current concepts. Pheochromocytoma: diagnosis, localization and management. New England Journal of Medicine, 311, 12981303.
  • 22
    Neumann, H.P., Bausch, B., McWhinney, S.R. et al. (2002) Germ-line mutations in nonsyndromic pheochromocytoma. New England Journal of Medicine, 346, 14591466.
  • 23
    Skinner, M.A., Moley, J.A., Dilley, W.G. et al. (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. New England Journal of Medicine, 353, 11051113.
  • 24
    Karasek, D., Frysak, Z. & Pacak, K. (2010) Genetic testing for pheochromocytoma. Current Hypertension Reports, 12, 456464.
  • 25
    Jafri, M. & Maher, E.R. (2012) The genetics of phaeochromcytoma: using clinical features to guide genetic testing. European Journal of Endocrinology, 166, 151158.
  • 26
    Erlic, Z., Rybicki, L., Peczkowska, M. et al. (2009) Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 15, 63786385.
  • 27
    Burnichon, N., Rohmer, V., Amar, L. et al. (2009) The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. Journal of Clinical Endocrinology and Metabolism, 94, 28172827.
  • 28
    Rattenberry, E., Vialard, L., Yeung, A. et al. (2013) A comprehensive next generation sequencing based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. Journal of Clinical Endocrinology and Metabolism, 98, E1248E1256.
  • 29
    McKenna, A., Hanna, M., Banks, E. et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Research, 20, 12971303.
  • 30
    Gilcrease, M.Z., Schmidt, L., Zbar, B. et al. (1995) Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. Human Pathology, 26, 13411346.
  • 31
    Loeb, D.B., Pericak-Vance, M.A., Stajich, J.M. et al. (1994) A novel mutation in the von Hippel-Lindau gene. Human Molecular Genetics, 3, 14231424.
  • 32
    Zankl, A., Duncan, E.L., Leo, P.J. et al. (2012) Multicentric carpotarsal osteolysis is caused by mutations clustering in the amino-terminal transcriptional activation domain of MAFB. American Journal of Human Genetics, 90, 494501.
  • 33
    Wetterstrand, K.. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP) Available at: [accessed 24 June 2013]
  • 34
    Crona, J., Verdugo, A.D., Granberg, D. et al. (2013) Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma. Endocrine Connect, 2, 104111.
  • 35
    Rieber, N., Zapatka, M., Lasitschka, B. et al. (2013) Coverage Bias and Sensitivity of Variant Calling for Four Whole-genome Sequencing Technologies. PLoS One, 8, e66621.
  • 36
    Asharani, P.V., Keupp, K., Semler, O. et al. (2012) Attenuated BMP1 function compromises osteogenesis, leading to bone fragility in humans and zebrafish. American Journal of Human Genetics, 90, 661674.
  • 37
    Aird, D., Ross, M.G., Chen, W.S. et al. (2011) Analyzing and minimizing PCR amplification bias in Illumina sequencing libraries. Genome Biology, 12, R18.
  • 38
    Statement of the American Society of Clinical Oncology. Genetic testing for cancer susceptibility, Adopted on February 20, 1996. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, (1996) 14:17301736; discussion 7-40.